Implication of soluble and membrane HLA class I and serum IL-10 in liver graft acceptance

Human Immunology

Volumn 60, Issue 6, 1999, Pages 500-509

  Minguela, Alfredo ^a   Torío, Alberto ^a   Marín, Luis ^a   Muro, Manuel ^a   Villar, Luisa M ^c   Díaz, Julian ^a   Ramírez, Pablo ^b   Parrilla, Pascual ^b   García Alonso, Ana M ^a   Álvarez López, María R ^a  

^a Section of Immunology   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^c HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Acute rejection; HLA class I expression; IL 10; Liver transplant tolerance; Soluble HLA class I

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; HLA ANTIGEN CLASS 1; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 10; METHYLPREDNISOLONE;

ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; GRAFT REJECTION; GRAFT SURVIVAL; HLA SYSTEM; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; TREATMENT OUTCOME;

CELL MEMBRANE; GRAFT REJECTION; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA-DR ANTIGENS; HUMANS; INTERLEUKIN-10; LIVER TRANSPLANTATION; PROGNOSIS; SOLUBILITY;

EID: 0033062427     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0198-8859(99)00016-6     Document Type: Article

References (46)

1. Mor E., Solomon H., Gibbs J.F., Holman M.J., Goldstein R.M., Husberg B.S., Gonwa T.A., Klintmalm G.B. Acute cellular rejection following liver transplantation clinical pathologic features and effect on outcome . Semin Liver Dis. 12:1992;28.
2. Kamada N: The liver as an immunosuppressive organ. In Tilney NL, Strom TB, Paul LC (eds): Transplantation biology: cellular and molecular aspects. Philadelphia: Lippincott-Raven, 1996.
3. Gonwa T.A., Nery J.R., Husberg B.S., Klintmalm G.B. Simultaneous liver and renal transplantation in man. Transplantation. 46:1988;690.
4. Alters S.E., Shizuru J.A., Ackerman J., Grossman D., Seydel K.B., Fathman C.G. Anti-CD4 mediates clonal anergy during transplantation tolerance induction. J Exp Med. 173:1991;491.
5. Dallman M.J., Shiho O., Page T.H., Wood K.J., Morris P.J. Peripheral tolerance to alloantigen results from altered regulation of the interleukin-2 pathway. J Exp Med. 173:1991;79.
6. Krensky A.M. T cells in autoimmunity and allograft rejection. Kidney Internat. 45:1994;S50.
7. Le Moine O., Marchant A., Durand F., Ickx B., Pradier O., Belghiti J., Abramovicz D., Gelin M., Goldman M., Deviére J. Systemic release of interleukin-10 during orthotopic liver transplant. Hepatology. 20:1994;889.
8. Alfrey E.J., Most D., Wang X., Lee L.K., Holm B., Krieger N.R., Sibley R.K., Huie P., Dafoe D.C. Interferon-gamma and interleukin-10 messenger RNA are up-regulated after orthotopic liver transplantation in tolerant rats evidence for cytokine-mediated immune dysregulation . Surgery. 118:1995;399.
9. Mirza D.F., Gumson B.K., Soonawalla Z., Pirenne J., Mayer A.D., Buckels J.A.C., McMaster P. Reduced acute rejection after liver transplantation with neoral-based triple immunosuppression. Lancet. 349:1997;701.
10. Nocera A., Pellicci R., Barocci S., Valente U., Cantarella S., Celada F., Callea F., Ceppa P., Leprini A. HLA antigens expression and cellular infiltrate analysis in rejected and accepted human liver allografts. Clin Transplant. 5:1991;23.
11. Steinhoff G., Wonigeit K., Pichlmayer R. Analysis of sequential changes in major histocompatibility complex expression in human liver grafts after transplantation. Transplantation. 45:1988;394.
12. Rouger P., Gugenheim J., Gene P., et al. Distribution of the MHC antigens after liver transplantation relationship with biochemical and histological parameters . Clin Exp Immunol. 80:1990;404.
13. Puppo F., Pellice R., Brenci S., Nocera A., Morelli N., Dardano G., Bertocchi M., Antonucci A., Ghio M., Scudeletti M., Barocci S., Valente U., Indiveri F. HLA class-I-soluble antigen serum levels in liver transplantation. A predictor marker of acute rejection. Hum Immunol. 40:1994;166.
14. Faustman D., Li X., Lin H.Y., Fu Y., Eisenbarth G., Avruch M., Guo J. Linkage of faulty major histocompatibility complex class-I to autoimmune diabetes. Science. 254:1991;1756.
15. Fu Y., Nathan D.M., Li F., Li X., Faustman D.L. Defective major histocompatibility complex class-I expression on lymphoid cells in autoimmunity. J Clin Invest. 91:1993;2301.
16. García-Alonso A.M., Minguela A., Muro M., Ontañón J., Torío A., Marín L., López-Segura P., Miras M., Álvarez-López M.R. CD28 expression on peripheral blood T lymphocytes after liver transplant up-regulation in acute rejection . Hum Immunol. 53:1997;64.
17. Minguela A., García-Alonso A.M., Marín L., Torío A., Sánchez-Bueno F., Bermejo J., Parrilla P., Álvarez-López M.R. Evidence of CD28 up-regulation on peripheral T cells before liver transplant acute rejection. Transplant Proc. 29:1997;499.
18. Barnstable C.J., Bodmer W.F., Brown G., Galfre G., Milstein C., Williams A.F., Zeigler A.Z. Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens. Cell. 14:1978;9.
19. Bernabeu C., Morago G., Ortiz de Landazuru M., Carreira J., Sánchez-Madrid F. Anticuerpos momoclonales específicos para antígenos de histocompatibilidad y activación de leucocitos humanos. Immunologia. 5:1986;83.
20. Ferreira A., Villar M.L., Álvarez-Cermeño J.C., García-Rodríguez M.C., Fontan G., Goanzález-Porqué P. Quantification of soluble serum class-I antigens in healthy volunteers and AIDS patients. Clin Chem Acta. 174:1988;207.
21. McDonald J.C., Gelder F.B., Aultman D.F., Landreneau M.D., McMillan R.W., Singh Y., Sorrells D., Liou W.H. HLA in human serum-quantification of class-I by enzyme immunoassay. Transplantation. 53:1992;445.
22. Buelow R., Burlinghan W.J., Clayberger C. Immunomodulation by soluble HLA class-I. Transplantation. 59:1995;649.
23. Mathew J.M., Shenoy S., Phelan D., Loweli J., Howard T., Mohanakumar T. Biochemical and immunological evaluation of donor-specific soluble HLA in the circulation of liver transplant recipients. Transplantation. 62:1996;217.
24. Clayberger C., Lyu S.C., Pouletty P., Kremsky A.M. Peptides corresponding to T cell receptor-HLA constant regions inhibit class-I restricted immune responses. Transplant Proc. 25:1993;477.
25. Grumet F.C., Kirshnaswamy S., See-Tho K., Filvaroff E., Hiraki D.D. Soluble form of an HLA-B7 class-I antigen (sHLA) specifically suppresses humoral alloimmunization. Hum Immunol. 40:1994;228.
26. Puppo F., Scudeletti M., Indiveri F., Ferrone S. Serum HLA class-I antigens markers and modulators of an immune response? Immunol Today. 16:1995;124.
27. Drouet M., Petit B., Peyronnet P., Aussel L., Venot J., Leroux-Robert C., Fauchet R. Soluble HLA class 1 antigens in kidney allograft recipients. Transplant Proc. 27:1995;1671.
28. Ontañón J., Muro M., García-Alonso A.M., Minguela A., Torío A., Bermejo J., Pons J.A., Campos M., Álvarez-López M.R. Effect of partial HLA-Class I match on acute rejection in viral preinfected human liver allograft recipients. Transplantation. 65:1998;1047.
29. Adamashvili I.M., Fraser P.A., McDonald J.C. Association of serum concentrations of soluble class-I HLA with HLA allotypes. Transplantation. 61:1996;984.
30. Sumimoto R., Kamada N. Specific suppression of allograft rejection by soluble class-I antigen and complexes with monoclonal antibody. Transplantation. 50:1990;678.
31. Hagihara M., Munkhbat B., Kanai N., Shimura T., Kiuchi T., Inomata Y., Tanaka K., Yamamoto K., Tsuji K. Serum soluble human leucocyte antigen class I in paediatric liver transplantation with live, related donors. Transpl Immunol. 5:1997;219.
32. Davies H.F.F.S., Pollard S.G., Calne R.Y. Soluble HLA antigens in the circulation of liver graft recipients. Transplantation. 47:1989;524.
33. Brieva J.A., Villar L.M., Leoro G., Álvarez-Cermeño J.C., Roldán E., González-Porqué P. Soluble HLA class-I antigen secretion by normal lymphocytes relationship with cell activation and effect of interferon-gamma . Clin Exp Immunol. 82:1990;390.
34. Villar L.M., Roy G., Lázaro I., Álvarez-Cermeno J.C., González M., Brieva J.A., De la Sen M.L., Leoro G., Bootello A., González-Porqué P. Detection of soluble class I molecules (non HLA-A or HLA-B) in serum, spleen membranes and lymphocytes in culture. Eur J Immunol. 19:1989;1835.
35. Aulitzky W.E., Grosse-Wilde H., Westhoff U., Tilg H., Aulitzky W., Gastl G., Herold M., Habber C. Enhanced serum levels of soluble HLA class-I molecules are induced by treatment with recombinant interferon-gamma (IFN-gamma). Clin Exp Immunol. 86:1991;236.
36. Koelman C.A., Mulder A., Jutte N.H.P.M., Vaessen L.M.B., Balk A.H.M.M., Weimar W., Doxiadis I.I.N., Claas F.H.J. The application of human monoclonal antibodies for monitoring donor derived soluble HLA class I molecules in the serum of heart transplant recipients. Hum Immunol. 59:1998;106.
37. Klompmaker L.J., Gouw A.S., Haagsma E.B., Ten Vergert E.M., Verwer R., Slooff M.J. Selective treatment of early acute rejection after liver transplantation effects on liver, infection rate, and outcome . Transpl Int. 10:1997;40.
38. Koppelman B., Neefjes J.J., de Vries J.E., de Waal-Malefyt R. Interleukin-10 down-regulates MHC class-II αβ peptide complexes at the membrane of monocytes by affecting arrival and recycling. Immunity. 7:1997;861.
39. de Waal-Malefyt R., Haanen J., Spits S., Roncarlo M.G., te-Velde A., Figfor C., Johnson K., Kastelin R., Yssel H., de Vries J.E. Interleukin 10 (IL-10) and viral IL-10 strongly reduces antigen-specific human T cell proliferation by diminishing the antigen presenting capacity of monocytes via downregulation of class II MHC expression. J Exp Med. 174:1991;915.
40. Ding L., Linsley P.S., Huang L.Y., Germain R.N., Shevach E.M. IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B-7 expression. J Immunol. 151:1993;1224.
41. Matsuda M., Salazar F., Peterson M., Masucci G., Hansson J., Pisa P., Zhang Q.J., Masucci M.G., Kiessling R. Interleukin 10 pre-treatment protects target cells from tumor- and allo-specific cytotoxic T cells and downregulates HLA class-I expression. J Exp Med. 180:1994;2371.
42. Rohrer J.W., Coggin J.H. CD8 T cell clones inhibit antitumor T cell function by secreting IL-10. J Immunol. 155:1995;5719.
43. Peguet-Navarro J., Moulon C., Caux C., Dalbiez-Gauthier C., Banchereau J., Schmitt D. Interleukin-10 inhibits the primary allogenic T cell response to human epidermal Langerhans cells. Eur J Immunol. 24:1994;884.
44. Lowry R.P., Konieczny B., Alexander D., Larsen C., Pearson T., Smith S., Narula S. Interleukin-10 eliminates anti-CD3 monoclonal antibody-induced mortality and prolong heart allograft survival in inbred mice. Transplant Proc. 27:1995;392.
45. Lang T., Krams S.M., Martinez O.M. Production of IL-4 and IL-10 does not lead to immune quiescence in vascularized human organ grafts. Transplantation. 62:1996;776.
46. Schwarz M., Majdic O., Knapp W., Holter W. High-level IL-10 production by monoclonal antibody-stimulated human T cells. Immunology. 86:1995;364.